Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 17/20 | 1.00 |
| ▸ | CAMKK1 | Q8N5S9 | 4/20 | 1.00 |
| ▸ | SGK1 | O00141 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 1.00 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 4/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-650394 SCHEMBL30753539 | 1.00 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| Gsk-650394 SCHEMBL3767908 | 1.00 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3767383 | 0.81 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3768084 | 0.79 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3767167 | 0.79 | CAMKK2 (0.76) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3762417 | 0.78 | CAMKK2 (0.74) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3764354 | 0.78 | CAMKK2 (0.82) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3766865 | 0.78 | CAMKK2 (1.00) | CAMKK2CAMKK1SGK1AURKASGK3 | |
| SCHEMBL3774587 | 0.77 | AXL (1.00) | CAMKK2SGK1AURKASGK2AXL | |
| SCHEMBL3759420 | 0.77 | AXL (1.00) | CAMKK2SGK1AURKASGK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119818491-A | Application of SGK1 inhibitor in preparation of medicine for treating endometriosis | 中国福利会国际和平妇幼保健院 | 2025-04-15 | — | — | CN | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | claimed |
| US-20230218634-A1 | METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS AND ANTI-ANDROGEN RECEPTOR THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPY | UNIVERSITY OF CHICAGO (US) | 2023-07-13 | — | — | US | claimed |
| US-11564932-B2 | Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy | THE UNIVERSITY OF CHICAGO (US) | 2023-01-31 | — | — | US | claimed |
| US-20220259654-A1 | COMPOSITIONS AND METHODS FOR XI CHROMOSOME REACTIVATION | UNIVERSITY OF MASSACHUSETTS (US) | 2022-08-18 | — | — | US | claimed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| CN-119950724-A | Application of SGK1 as marker in tumor immunotherapy | 北京大学 | 2025-05-09 | — | — | CN | disclosed |
| CN-119818491-A | Application of SGK1 inhibitor in preparation of medicine for treating endometriosis | 中国福利会国际和平妇幼保健院 | 2025-04-15 | — | — | CN | disclosed |
| CN-119818491-A | Application of SGK1 inhibitor in preparation of medicine for treating endometriosis | 中国福利会国际和平妇幼保健院 | 2025-04-15 | — | — | CN | disclosed |
| EP-4529477-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-115006536-A | Application of Sgk1 as target in preparation of medicine for inhibiting gluconeogenesis | 上海交通大学医学院附属瑞金医院 | 2022-09-06 | — | — | CN | disclosed |
| US-20220259654-A1 | COMPOSITIONS AND METHODS FOR XI CHROMOSOME REACTIVATION | UNIVERSITY OF MASSACHUSETTS (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-11389432-B2 | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent | CORCEPT THERAPEUTICS INCORPORATED (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3982922-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | Technical University of Denmark (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-20220062378-A1 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | UNIVERSITY OF COPENHAGEN (DK) | 2022-03-03 | — | — | US | disclosed |
| US-11234971-B2 | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent | CORCEPT THERAPEUTICS INCORPORATED (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | CAMKK2 1862/4885CAMKK1 2729/4885SGK1 1590/4885 |
| US-11389432-B2 | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent | NR3C1, GRK2, GRK3 | CAMKK2 228/4885CAMKK1 307/4885SGK1 4/4885 |
| US-11234971-B2 | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent | NR3C1, GRK4, GRK5 | CAMKK2 1027/4885CAMKK1 1449/4885SGK1 60/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | CAMKK2 1213/4885CAMKK1 1630/4885SGK1 3969/4885 |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | LIPA, LIPE, CEL | CAMKK2 1273/4885CAMKK1 1174/4885SGK1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.